Cargando…

Acute Kidney Injury: Biomarker-Guided Diagnosis and Management

Acute kidney injury (AKI) is a common clinical syndrome that is characterized by abnormal renal function and structure. The Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference in 2019 reviewed the stages of AKI and the definitions of AKI-related terminologies, and discussed th...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoon, Soo-Young, Kim, Jin-Sug, Jeong, Kyung-Hwan, Kim, Su-Kang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8953384/
https://www.ncbi.nlm.nih.gov/pubmed/35334515
http://dx.doi.org/10.3390/medicina58030340
_version_ 1784675837941907456
author Yoon, Soo-Young
Kim, Jin-Sug
Jeong, Kyung-Hwan
Kim, Su-Kang
author_facet Yoon, Soo-Young
Kim, Jin-Sug
Jeong, Kyung-Hwan
Kim, Su-Kang
author_sort Yoon, Soo-Young
collection PubMed
description Acute kidney injury (AKI) is a common clinical syndrome that is characterized by abnormal renal function and structure. The Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference in 2019 reviewed the stages of AKI and the definitions of AKI-related terminologies, and discussed the advances in the last decade. Along with serum creatinine level and urine output, more accurate novel biomarkers for predicting AKI are being applied for the early detection of renal dysfunction. A literature search was conducted in PubMed, Scopus, Medline, and ClinicalTrials.gov using the terms AKI and biomarker, combined with diagnosis, management, or prognosis. Because of the large volume of data (160 articles) published between 2005 and 2022, representative literature was chosen. A number of studies have demonstrated that new biomarkers are more sensitive in detecting AKI in certain populations than serum creatinine and urine output according to the recommendations from the Acute Disease Quality Initiative Consensus Conference. To be specific, there is a persistently unresolved need for earlier detection of patients with AKI before AKI progresses to a need for renal replacement therapy. Biomarker-guided management may help to identify a high-risk group of patients in progression to severe AKI, and decide the initiation time to renal replacement therapy and optimal follow-up period. However, limitations such as biased data to certain studied populations and absence of cutoff values need to be solved for worldwide clinical use of biomarkers in the future. Here, we provide a comprehensive review of biomarker-based AKI diagnosis and management and highlight recent developments.
format Online
Article
Text
id pubmed-8953384
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-89533842022-03-26 Acute Kidney Injury: Biomarker-Guided Diagnosis and Management Yoon, Soo-Young Kim, Jin-Sug Jeong, Kyung-Hwan Kim, Su-Kang Medicina (Kaunas) Review Acute kidney injury (AKI) is a common clinical syndrome that is characterized by abnormal renal function and structure. The Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference in 2019 reviewed the stages of AKI and the definitions of AKI-related terminologies, and discussed the advances in the last decade. Along with serum creatinine level and urine output, more accurate novel biomarkers for predicting AKI are being applied for the early detection of renal dysfunction. A literature search was conducted in PubMed, Scopus, Medline, and ClinicalTrials.gov using the terms AKI and biomarker, combined with diagnosis, management, or prognosis. Because of the large volume of data (160 articles) published between 2005 and 2022, representative literature was chosen. A number of studies have demonstrated that new biomarkers are more sensitive in detecting AKI in certain populations than serum creatinine and urine output according to the recommendations from the Acute Disease Quality Initiative Consensus Conference. To be specific, there is a persistently unresolved need for earlier detection of patients with AKI before AKI progresses to a need for renal replacement therapy. Biomarker-guided management may help to identify a high-risk group of patients in progression to severe AKI, and decide the initiation time to renal replacement therapy and optimal follow-up period. However, limitations such as biased data to certain studied populations and absence of cutoff values need to be solved for worldwide clinical use of biomarkers in the future. Here, we provide a comprehensive review of biomarker-based AKI diagnosis and management and highlight recent developments. MDPI 2022-02-23 /pmc/articles/PMC8953384/ /pubmed/35334515 http://dx.doi.org/10.3390/medicina58030340 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Yoon, Soo-Young
Kim, Jin-Sug
Jeong, Kyung-Hwan
Kim, Su-Kang
Acute Kidney Injury: Biomarker-Guided Diagnosis and Management
title Acute Kidney Injury: Biomarker-Guided Diagnosis and Management
title_full Acute Kidney Injury: Biomarker-Guided Diagnosis and Management
title_fullStr Acute Kidney Injury: Biomarker-Guided Diagnosis and Management
title_full_unstemmed Acute Kidney Injury: Biomarker-Guided Diagnosis and Management
title_short Acute Kidney Injury: Biomarker-Guided Diagnosis and Management
title_sort acute kidney injury: biomarker-guided diagnosis and management
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8953384/
https://www.ncbi.nlm.nih.gov/pubmed/35334515
http://dx.doi.org/10.3390/medicina58030340
work_keys_str_mv AT yoonsooyoung acutekidneyinjurybiomarkerguideddiagnosisandmanagement
AT kimjinsug acutekidneyinjurybiomarkerguideddiagnosisandmanagement
AT jeongkyunghwan acutekidneyinjurybiomarkerguideddiagnosisandmanagement
AT kimsukang acutekidneyinjurybiomarkerguideddiagnosisandmanagement